骨质疏松症与肠道微生物群的交叉对话。

IF 2 Q2 ORTHOPEDICS
Shiva Shankar Jha, Naveen Jeyaraman, Madhan Jeyaraman, Swaminathan Ramasubramanian, Sathish Muthu, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana
{"title":"骨质疏松症与肠道微生物群的交叉对话。","authors":"Shiva Shankar Jha, Naveen Jeyaraman, Madhan Jeyaraman, Swaminathan Ramasubramanian, Sathish Muthu, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana","doi":"10.5312/wjo.v16.i3.102274","DOIUrl":null,"url":null,"abstract":"<p><p>The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal, playing a crucial role in various physiological functions. These microbes generally live in harmony with the host; however, when dysbiosis occurs, it can contribute to the pathogenesis of diseases, including osteoporosis. Osteoporosis, a systemic skeletal disease characterized by reduced bone mass and increased fracture risk, has attracted significant research attention concerning the role of gut microbes in its development. Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation, modulation of the gut-brain axis, and regulation of the intestinal barrier and nutrient absorption. These microbes can enhance bone mass by inhibiting osteoclast differentiation, inducing apoptosis, reducing bone resorption, and promoting osteoblast proliferation and maturation. Despite these promising findings, the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation. Notably, gut microbiota has been increasingly studied for their potential in early diagnosis, intervention, and as an adjunct therapy for osteoporosis, suggesting a growing utility in improving bone health. Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.</p>","PeriodicalId":47843,"journal":{"name":"World Journal of Orthopedics","volume":"16 3","pages":"102274"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924030/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cross-talks between osteoporosis and gut microbiome.\",\"authors\":\"Shiva Shankar Jha, Naveen Jeyaraman, Madhan Jeyaraman, Swaminathan Ramasubramanian, Sathish Muthu, Gabriel Silva Santos, Lucas Furtado da Fonseca, José Fábio Lana\",\"doi\":\"10.5312/wjo.v16.i3.102274\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal, playing a crucial role in various physiological functions. These microbes generally live in harmony with the host; however, when dysbiosis occurs, it can contribute to the pathogenesis of diseases, including osteoporosis. Osteoporosis, a systemic skeletal disease characterized by reduced bone mass and increased fracture risk, has attracted significant research attention concerning the role of gut microbes in its development. Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation, modulation of the gut-brain axis, and regulation of the intestinal barrier and nutrient absorption. These microbes can enhance bone mass by inhibiting osteoclast differentiation, inducing apoptosis, reducing bone resorption, and promoting osteoblast proliferation and maturation. Despite these promising findings, the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation. Notably, gut microbiota has been increasingly studied for their potential in early diagnosis, intervention, and as an adjunct therapy for osteoporosis, suggesting a growing utility in improving bone health. Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.</p>\",\"PeriodicalId\":47843,\"journal\":{\"name\":\"World Journal of Orthopedics\",\"volume\":\"16 3\",\"pages\":\"102274\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924030/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Orthopedics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5312/wjo.v16.i3.102274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ORTHOPEDICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Orthopedics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5312/wjo.v16.i3.102274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

摘要

肠道微生物群是指生活在人体消化道内的一个庞大的微生物群落,在各种生理功能中起着至关重要的作用。这些微生物通常与宿主和谐相处;然而,当生态失调发生时,它可以促进疾病的发病机制,包括骨质疏松症。骨质疏松症是一种以骨量减少和骨折风险增加为特征的全身性骨骼疾病,肠道微生物在其发展中的作用引起了人们的广泛关注。分子生物学的进展强调了肠道微生物群通过免疫调节、肠脑轴调节、肠屏障和营养吸收调节等机制对骨质疏松症的影响。这些微生物可以通过抑制破骨细胞分化、诱导细胞凋亡、减少骨吸收、促进成骨细胞增殖和成熟来增强骨量。尽管有这些有希望的发现,针对骨质疏松症的肠道微生物的治疗效果需要进一步的研究。值得注意的是,肠道微生物群在骨质疏松症的早期诊断、干预和辅助治疗方面的潜力已经得到越来越多的研究,这表明它们在改善骨骼健康方面的作用越来越大。为了充分阐明肠道微生物调节在骨质疏松症治疗中的治疗潜力和临床应用,需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cross-talks between osteoporosis and gut microbiome.

The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal, playing a crucial role in various physiological functions. These microbes generally live in harmony with the host; however, when dysbiosis occurs, it can contribute to the pathogenesis of diseases, including osteoporosis. Osteoporosis, a systemic skeletal disease characterized by reduced bone mass and increased fracture risk, has attracted significant research attention concerning the role of gut microbes in its development. Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation, modulation of the gut-brain axis, and regulation of the intestinal barrier and nutrient absorption. These microbes can enhance bone mass by inhibiting osteoclast differentiation, inducing apoptosis, reducing bone resorption, and promoting osteoblast proliferation and maturation. Despite these promising findings, the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation. Notably, gut microbiota has been increasingly studied for their potential in early diagnosis, intervention, and as an adjunct therapy for osteoporosis, suggesting a growing utility in improving bone health. Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
814
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信